GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
3

3D Global Biotech 6808.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

26.00

-2.07%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About 3D Global Biotech

Its shares trade on Taipei Exchange under the ticker 6808.TWO. It has been listed since 25 December 2020. In the fiscal year to 31 December 2025, it reported revenue of TWD 206.7m and net income of TWD 66.5m. At that date it held total assets of TWD 1.09bn and shareholders' equity of TWD 984.5m.

3D Global Biotech, Inc. engages in the research and development of biological three dimensional printing technology. The company is headquartered in Taipei, New Taipei. The company went IPO on 2020-12-25. The firm mainly provides hard tissue reconstruction medical materials and soft tissue reconstruction medical materials. The hard tissue reconstruction medical materials mainly provide customized services for dental medical materials, original equipment manufacturer services for customized products of cranial implants, and orthopedics and dental reconstruction medical materials DGRA01: α-Former bone filling materials and the second-level medical equipment product of craniofacial jaw reconstruction medical materials DGRA03: SmileAlign transparent correction system. The soft tissue reconstruction medical materials mainly include bio-ink product DGRC02: 3D Bioture EX water gel stent.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
25 Dec 2020
Employees
32

Leadership

Pay as last reported

  • Gengliang OuChairman of the Board, since 2025
  • Ciying HongGeneral Manager
  • Chi-Wen ChenDeputy General Manager- Business Division
  • Ms. Ruiwen HuangDeputy General Manager, since 2024
  • Yichen LiuDeputy General Manager-New Market & Product Development Division
  • Wanru LiCorporate Governance Officer
  • Mr. Ming-Hsien ChenDirector
  • Xudong LeeDirector
  • Zhaoxian ZhengDirector
  • Bingyan CaiIndependent Director
  • Xuanzhe LiuIndependent Director
  • Mr. Qintang QiuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Taipei, New Taipei
  • Offers customized services for dental medical materials
  • Provides hard tissue reconstruction medical materials including DGRA01

Weaknesses

  • Limited to biotechnology sector
  • No mention of revenue or market share
  • IPO in 2020-12-25 with no financial data provided

Opportunities

  • Expansion into soft tissue reconstruction medical materials
  • Growth in 3D printing technology applications
  • Potential for international market expansion

Threats

  • Untrusted source description may contain inaccuracies
  • Dependence on specific medical material products
  • Competition in biotechnology sector

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.